Format

Send to

Choose Destination
See comment in PubMed Commons below
Mediterr J Hematol Infect Dis. 2009 Dec 28;1(2):e2009030. doi: 10.4084/MJHID.2009.030.

Clinical aspects and therapy of sporadic burkitt lymphoma.

Author information

1
Istituto di Ematologia, Università Cattolica S. Cuore, Roma.

Abstract

Burkitt's lymphoma is a highly aggressive mature B-cell neoplasm consisting of endemic, sporadic, and immunodeficiency-associated variants, sharing many morphologic and immunophenotypic features. It is characterized by a high proliferation rate and propensity for extranodal sites such as gastrointestinal tract and reproductive organs. Brief-duration, high-intensity chemotherapy regimens including aggressive central nervous system prophylaxis have had remarkable success in the treatment of this disease in the sporadic form, with very high complete remission rate and overall survival in adults. Although Burkitt's lymphoma is extremely chemosensitive, biologically targeted therapies should be developed, because current treatment options are suboptimal for patients with poor prognostic features or with relapsed disease.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Catholic University in Rome, Institute of Hematology Icon for PubMed Central
    Loading ...
    Support Center